1-for-40 Reverse Split Set for October 23 as Nasdaq Delisting Risk Looms
PASW is trading near its 52-week low of $0.092 (3.3% above the low) on light trading volume (0.1× avg).
Summary
Ping An Biomedical's board approved a 1-for-40 reverse split of its class A and class B ordinary shares, with split-adjusted trading on Nasdaq starting October 23, 2026, when the par value rises from $0.0000625 to $0.0025 per class A and class B share. Outstanding shares fall from roughly 125.1 million to about 3.13 million, and the class A CUSIP changes to G5880S139. The move comes after the company disclosed in its September 11 6-K that it remains at risk of Nasdaq delisting, and follows the August auditor swap from WWC to Edston Global. At a $0.0951 share price near the 52-week low, the consolidation is a compliance maneuver to lift the bid above Nasdaq's $1 minimum rather than a change in the underlying business. The company reported a first-half 2026 profit of RMB 4.83 million, but the reverse split alone does not resolve the listing deficiency — watch whether Nasdaq confirms regained compliance after the October 23 effective date.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — Ping An Biomedical's par value rises from $0.0000625 to $0.0025 per class A and class B share upon the 1-for-40 reverse split effective October 23, 2026.
At the time of this announcement, PASW was trading at $0.10 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $11.9M. The 52-week trading range was $0.09 to $0.80. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.